Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (4): 303-306.DOI: 10.3969/j.issn.1673-8640.2023.04.001
GAO Feng
Received:
2023-03-23
Revised:
2023-03-30
Online:
2023-04-28
Published:
2023-06-21
CLC Number:
GAO Feng. Clinical application of novel tumor biomarkers:prospects and challenges[J]. Laboratory Medicine, 2023, 38(4): 303-306.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.04.001
1. |
IGNATIADIS M, SLEDGE G W, JEFFREY S S. Liquid biopsy enters the clinic-implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5):297-312.
DOI |
2. |
RING A, NGUYEN-STRÄULI B D, WICKI A, et al. Biology, vulnerabilities and clinical applications of circulating tumour cells[J]. Nat Rev Cancer, 2023, 23(2):95-111.
DOI |
3. |
LUO H, WEI W, YE Z, et al. Liquid biopsy of methylation biomarkers in cell-free DNA[J]. Trends Mol Med, 2021, 27(5):482-500.
DOI PMID |
4. |
SLACK F J, CHINNAIYAN A M. The role of non-coding rnas in oncology[J]. Cell, 2019, 179(5):1033-1055.
DOI PMID |
5. |
FREZZETTI D, DE LUCA A, NORMANNO N. Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients[J]. J Thorac Dis, 2019, 11(Suppl 9):S1252-S1256.
DOI URL |
6. |
DENG Z, WU S, WANG Y, et al. Circulating tumor cell isolation for cancer diagnosis and prognosis[J]. EBioMedicine, 2022, 83:104237.
DOI URL |
7. |
ALIX-PANABIÈRES C, PANTEL K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016, 6(5):479-491.
DOI URL |
8. |
KELLER L, PANTEL K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells[J]. Nat Rev Cancer, 2019, 19(10):553-567.
DOI PMID |
9. |
WANG Y, KIM T H, FOULADDEL S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer[J]. Sci Rep, 2019, 9(1):566.
DOI PMID |
10. |
BIDARD F C, PEETERS D J, FEHM T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer:a pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4):406-414.
DOI URL |
11. |
SCHER H I, HELLER G, MOLINA A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2015, 33(12):1348-1355.
DOI PMID |
12. | HELLER G, MCCORMACK R, KHEOH T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer:a comparison with prostate-specific antigen across five randomized phase Ⅲ clinical trials[J]. J Clin Oncol, 2018, 36(6):572-580. |
13. |
AHN J C, TENG P C, CHEN P J, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis,prognostication,and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73(1):422-436.
DOI URL |
14. |
ZHANG W, LI N, LIN L, et al. Metabolism-based capture and analysis of circulating tumor cells in an open space[J]. Anal Chem, 2021, 93(18):6955-6960.
DOI PMID |
15. |
KHOO B L, GRENCI G, JING T, et al. Liquid biopsy and therapeutic response:circulating tumor cell cultures for evaluation of anticancer treatment[J]. Sci Adv, 2016, 2(7):e1600274.
DOI URL |
16. | KANWAL R, GUPTA K, GUPTA S. Cancer epigenetics:an introduction[J]. Methods Mol Biol, 2015, 1238:3-25. |
17. | SPAINHOUR J C, LIM H S, YI S V, et al. Correlation patterns between DNA methylation and gene expression in the cancer genome atlas[J]. Cancer Inform, 2019, 18:1176935119828776. |
18. |
MORAN S, MARTÍNEZ-CARDÚS A, SAYOLS S, et al. Epigenetic profiling to classify cancer of unknown primary:a multicentre,retrospective analysis[J]. Lancet Oncol, 2016, 17(10):1386-1395.
DOI URL |
19. |
LAMB Y N, DHILLON S. Epi proColon® 2.0 CE:a blood-based screening test for colorectal cancer[J]. Mol Diagn Ther, 2017, 21(2):225-232.
DOI URL |
20. |
ZHANG C, YU W, WANG L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis[J]. J Cancer, 2017, 8(17):3585-3591.
DOI PMID |
21. |
XIE Y, ZHANG Y, DU L, et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer[J]. Mol Oncol, 2018, 12(5):648-658.
DOI PMID |
22. |
JENIKE A E, HALUSHKA M K. MiR-21:a non-specific biomarker of all maladies[J]. Biomark Res, 2021, 9(1):18.
DOI |
23. |
ASHIRBEKOV Y, ABAILDAYEV A, OMARBAYEVA N, et al. Combination of circulating miR-145-5p/miR-191-5p as biomarker for breast cancer detection[J]. PeerJ, 2020, 8:e10494.
DOI URL |
24. |
NG E K, LI R, SHIN V Y, et al. Circulating microRNAs as specific biomarkers for breast cancer detection[J]. PLoS One, 2013, 8(1):e53141.
DOI URL |
25. |
KARAMANOS N K, THEOCHARIS A D, PIPERIGKOU Z, et al. A guide to the composition and functions of the extracellular matrix[J]. FEBS J, 2021, 288(24):6850-6912.
DOI PMID |
26. |
GIUSSANI M, TRIULZI T, SOZZI G, et al. Tumor extracellular matrix remodeling:new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors[J]. Cells, 2019, 8(2):81.
DOI URL |
27. |
ALASEEM A, ALHAZZANI K, DONDAPATI P, et al. Matrix metalloproteinases:a challenging paradigm of cancer management[J]. Semin Cancer Biol, 2019, 56:100-115.
DOI URL |
28. |
NECULA L, MATEI L, DRAGU D, et al. Collagen family as promising biomarkers and therapeutic targets in cancer[J]. Int J Mol Sci, 2022, 23(20):12415.
DOI URL |
29. |
MOON P G, LEE J E, CHO Y E, et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer[J]. Oncotarget, 2016, 7(26):40189-40199.
DOI URL |
30. |
RESOVI A, BANI M R, PORCU L, et al. Soluble stroma-related biomarkers of pancreatic cancer[J]. EMBO Mol Med, 2018, 10(8):e8741.
DOI URL |
31. |
CHEN L, HUAN X, XIAO G H, et al. Osteopontin and its downstream carcinogenic molecules:regulatory mechanisms and prognostic value in cancer progression[J]. Neoplasma, 2022, 69(6):1253-1269.
DOI URL |
32. |
WU M, CAO M, HE Y, et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis[J]. FASEB J, 2015, 29(4):1290-1298.
DOI PMID |
33. |
ZHANG G, LU R, WU M, et al. Colorectal cancer-associated-6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis[J]. FEBS J, 2019, 286(16):3148-3163.
DOI URL |
[1] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[2] | WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691. |
[3] | ZHANG Min, WANG Binyu, CHI Weiqun, LIU Yu. Research progress of exosomal non-coding RNA as biomarkers for disease diagnosis [J]. Laboratory Medicine, 2023, 38(6): 594-598. |
[4] | WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195. |
[5] | ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210. |
[6] | GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996. |
[7] | WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45. |
[8] | WANG Yuqing, ZHANG Yue, XU Wen, CUI Zhongqi. Construction and clinical application of colon cancer prognostic risk model of ferroptosis-related lncRNA [J]. Laboratory Medicine, 2022, 37(8): 720-728. |
[9] | LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740. |
[10] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609. |
[11] | JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, DONG Wei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Yifei. Expression level of lncRNA SNHG15 in gastric cancer and clinical significance [J]. Laboratory Medicine, 2022, 37(5): 409-412. |
[12] | YU Qi, SUN Yi, WANG Qiongli, CAI Yiting, LI Li. Application of morphological analysis of circulating tumor cells in clinical examination [J]. Laboratory Medicine, 2022, 37(3): 264-269. |
[13] | ZHOU Huan, TANG Ying, DU Cuiping, YANG Yang, FENG Huijie, QIU Miaoxin, YAN Peiyi, CAI Xiaoyao, JIN Shu. Effect of long non-coding RNA SNHG5 on the transcriptome of human hypopharyngeal carcinoma cells and clinical significance [J]. Laboratory Medicine, 2022, 37(3): 281-287. |
[14] | SHEN Suya, HUANG Jianzhao, LI Xiaohuai. Progress on the enrichment technology of circulating tumor cells [J]. Laboratory Medicine, 2022, 37(1): 91-96. |
[15] | YANG Chaomei, FENG Jie, LANG Lei, YAN Guangtao. Clinical application value of CTC combined determination with CEA and CA125 in colorectal cancer [J]. Laboratory Medicine, 2021, 36(9): 901-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||